Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update

Hesketh, Paul J.; Kris, Mark G.; Basch, Ethan; Bohlke, Kari; Barbour, Sally Y.; Clark‐Snow, Rebecca; Danso, Michael A.; Dennis, Kristopher; Dupuis, L. Lee; Dusetzina, Stacie B.; Eng, Cathy; Feyer, Petra; Jordan, Karin; Noonan, Kimberly; Sparacio, Dee; Somerfield, Mark R.; Lyman, Gary H.

doi:10.1200/jco.2010.34.4614

Cited by 801 publications

(479 citation statements)

References 28 publications

Supporting

Mentioning

430

Contrasting

Unclassified

Order By: Relevance

“…Guidelines currently recommend that a 5‐HT 3 RA and dexamethasone be used in all patients receiving MEC and that patients with additional CINV risk factors also receive an NK‐1 RA 4, 5…”

Section: Introductionmentioning

confidence: 99%

Efficacy of the neurokinin‐1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin‐based chemotherapy

Hesketh

Schnadig

Schwartzberg

et al. 2016

Cancer

Self Cite

View full text Add to dashboard Cite

BACKGROUNDRolapitant, a novel neurokinin‐1 receptor antagonist, provided effective protection against chemotherapy‐induced nausea and vomiting (CINV) in a randomized, double‐blind phase 3 trial of patients receiving moderately emetogenic chemotherapy or an anthracycline and cyclophosphamide regimen. The current analysis explored the efficacy and safety of rolapitant in preventing CINV in a subgroup of patients receiving carboplatin.METHODSPatients were randomized 1:1 to receive oral rolapitant (180 mg) or a placebo 1 to 2 hours before chemotherapy administration; all patients received oral granisetron (2 mg) on days 1 to 3 and oral dexamethasone (20 mg) on day 1. A post hoc analysis examined the subgroup of patients receiving carboplatin in cycle 1. The efficacy endpoints were as follows: complete response (CR), no emesis, no nausea, no significant nausea, complete protection, time to first emesis or use of rescue medication, and no impact on daily life.RESULTSIn the subgroup administered carboplatin‐based chemotherapy (n = 401), a significantly higher proportion of patients in the rolapitant group versus the control group achieved a CR in the overall phase (0‐120 hours; 80.2% vs 64.6%; P < .001) and in the delayed phase (>24‐120 hours; 82.3% vs 65.6%; P < .001) after chemotherapy administration. Superior responses were also observed by the measures of no emesis, no nausea, and complete protection in the overall and delayed phases and by the time to first emesis or use of rescue medication. The incidence of treatment‐emergent adverse events was similar for the rolapitant and control groups.CONCLUSIONSRolapitant provided superior CINV protection to patients receiving carboplatin‐based chemotherapy in comparison with the control. These results support rolapitant use as part of the antiemetic regimen in carboplatin‐treated patients. Cancer 2016;122:2418–2425. © 2016 American Cancer Society.

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy of the neurokinin‐1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin‐based chemotherapy

Hesketh

Schnadig

Schwartzberg

et al. 2016

Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…"bolesti kretanja"); -ima anamnezu povraćanja u trudnoći; -iskusio mučninu i povraćanje u prethodnim ciklusima hemioterapije, pogotovu ako su mučnina i / ili povraćanje bili težeg stepena -anksiozan -koristi neke druge lekove (na primer, nesteroidne antiinflamatorne lekove, opioide ili antibiotike) -Hronična teška zloupotreba alkoholnih pića smanjuje rizik za nastanak mučnine i povraćanja uzrokovanih hemioterapijom. (7,8,9,10) Najvažniji faktor za ispoljavanje mučnine i povraćanja jeste emetogentost citotoksičnih lekova i njome se treba rukovoditi u terapijskom pristupu u prevenciji mučnine i povraćanja. Kada se radi o hemioterapijskim režimima koji obuhvataju dva ili više citotoksična leka, emetogenost režima određuje emetogenost najemetogenijeg leka u kombinaciji.…”

Section: Faktori Rizika Pacijentaunclassified

“…Kada se radi o hemioterapijskim režimima koji obuhvataju dva ili više citotoksična leka, emetogenost režima određuje emetogenost najemetogenijeg leka u kombinaciji. (6,7,9,10) Mučnina i povraćanje koji su izazvani hemioterapijom negativno utiču na kvalitet života pacijenata i na potrošnju sredstava zdravstvene zaštite. Kontrola emetegenosti hemioterapije i dalje ostaje izazov , a nedostatak efikasne komunikacije između pacijenta i lekara i medicinskih sestara je istaknut u literaturi kao glavna prepreka za optimalnu kontrolu.…”

Section: Faktori Rizika Pacijentaunclassified

Feasibility of using the Multinational Association of Supportive Care in Cancer antiemesis tool for assessment of chemotherapy-induced nausea and vomiting at Institute for Oncology and Radiology of Serbia and palliative care team

Bakić¹,

Dimitrijević²,

Bošnjak³

2015

Sestrinska rec

View full text Add to dashboard Cite

jenta jeste psihološka podrška koja potiče iz odličnog odnosa lekar-sestra-pacijent.Kao primer možemo predstaviti pacijenta sa auto imunim poremećajem -Birgerova bolest. Često kao jedna od najtežih bolesti krvnih sudova ovaj poremećaj može dovesti do komplikacija i uvesti pacijenta u stanje koje zahteva palijativnu negu. Bolest je vrlo teška, a prognoza loša. Zahvata pojedine segmente srednje velikih i male krvne sudove nogu, ruku, nerava, retko mozga i srca. Takođe komplikacije mogu nastati i zbog embolija, dijabetesa ili stanja koja mogu nastati kao posledica aktuelnog oboljenja.Pacijent je osoba koja se nalazi u neizvesnoj situaciji i u strahu od ishoda bolesti. Preko puta sebe ima nepoznatu osobu kojoj mora reći svoje najintimnije stvari. Za većinu pacijenata ovo je veoma teška situacija, dok se može desiti da zdravstveni radnici, krajnje neprofesionalno to zaboravljaju, i ne ophode se prema pacijentima uvek korektno, sa empatijom i poštovanjem njihove ličnosti. Od ljubaznosti zdravstvenih radnika u velikoj meri zavisi koliko će pacijenti prihvatiti svoju dijagnozu, terapiju, kakva će biti prognoza bolesti. Lekari i sestre kao i ceo tim koji učestvuje u rehabilitaciji ili pružanju palijativnog zbrinjavanja, imaju dužnost da doprinesu smanjenju anksioznosti pacijenata tokom pregleda svojim empatskim stavom, osmehom, toplinom, razumevanjem, poštovanjem.Kada se postigne dostojanstven nivo komunikacije i kada se ispoštuje kodeks ponašanja treba obratiti pažnju na neverbalnu komunikaciju koja je izuzetno važna jer savremena istraživanja kažu da 60% kompletnog prvog utiska se formira na osnovu neverbalne komunikacije.Kada se sve gore navedeno uzme u obzir može se reći da su medicinske sestre sa definisanim kompentencijama, neizostavna i važna karika u lancu medicinske i zdravstvene nege, rehabilitacije ili palijativnog zbrinjavanja.

show abstract

“…The guidelines recommend using the combination of dexamethasone, 5-hydroxytryptamine 3 (5-HT 3 ) receptor antagonist and neurokinin-1 (NK 1 ) receptor antagonist for prevention of CINV associated with HEC (6)(7)(8)(9). It has been shown that adherence to the antiemetic guideline leads to an improvement of the control of CINV (10)(11)(12)(13)(14)(15)(16)(17).…”

mentioning

confidence: 99%

“…Cisplatin is classified as chemotherapy with high emetic risk (HEC) in several guidelines for prevention of chemotherapy-induced nausea and vomiting (CINV) (6)(7)(8)(9).…”

mentioning

confidence: 99%

Control of Nausea Based on Risk Analysis in Patients with Esophageal and Gastric Cancer Who Received Cisplatin-based Chemotherapy

Fujii

Iihara

Kajikawa

et al. 2017

View full text Add to dashboard Cite

Cisplatin is commonly used for esophageal and gastric cancer, however, the agent has high emetic risk, classified as highly emetic chemotherapy. Ohtsu et al. demonstrated in patients with advanced gastric cancer that 5-fluorouracil (5-FU) plus cisplatin led to a significantly higher tumor response rate and longer median progression-free survival but not overall survival as compared with 5-FU alone (1). Koizumi et al. also reported in phase 3 study comparing the effect of S-1 alone and its combination with cisplatin in patients with advanced gastric cancer that the combination was superior to S-1 alone in prolonging median progression-free survival (HR: 0.57; p<0.0001) as well as median overall survival (HR: 0.77; p=0.04) but led to more severe adverse drug reactions, including nausea and vomiting (2). Thus, oral fluoropyrimidine and cisplatin combination chemotherapy is currently used as the first-line treatment option for unresectable advanced gastric cancer. On the other hand, Bang et al. reported in patients with human epidermal growth factor receptor 2 (HER2)-positive gastric or gastro-oesophageal junction cancer that addition of trastuzumab (monoclonal antibody to HER2) to chemotherapy led to ignificantly longer median overall survival than chemotherapy alone (3). Thus, oral fluoropyrimidine, cisplatin and trastuzumab combination chemotherapy is currently regarded as the standard chemotherapy for HER2-positive gastric cancer.On the other hand, cisplatin with 5-FU regimen is recommended as neoadjuvant chemotherapy for stage II/III thoracic esophageal cancer and unresectable progressive recurrent esophageal cancer (4, 5).Cisplatin is classified as chemotherapy with high emetic risk (HEC) in several guidelines for prevention of chemotherapy-induced nausea and vomiting (CINV) (6-9). 6831

show abstract

Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update

Cited by 801 publications

References 28 publications

Efficacy of the neurokinin‐1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin‐based chemotherapy

Efficacy of the neurokinin‐1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin‐based chemotherapy

Feasibility of using the Multinational Association of Supportive Care in Cancer antiemesis tool for assessment of chemotherapy-induced nausea and vomiting at Institute for Oncology and Radiology of Serbia and palliative care team

Control of Nausea Based on Risk Analysis in Patients with Esophageal and Gastric Cancer Who Received Cisplatin-based Chemotherapy

Contact Info

Product

Resources

About